Los Angeles CRS for the MACS/WIHS Combined Cohort Study

摘要 UCLA多中心艾滋病队列研究（MACS）/妇女跨机构临床研究中心（CRS） ‐ ‐ ‐‐ HIV研究（WIHS）联合队列研究（CCS）建议继续记录临床、免疫学、 ‐‐ ‐ 生理，行为，病毒学，遗传和心理社会变化的艾滋病毒感染和未感染的男子， ‐‐ 与男性发生性关系（MSM）。这包括拟议的研究，以记录这些变化的男男性接触者招募 ‐ 以前，以及计划招募新的未经治疗和最近治疗的艾滋病毒感染的男男性行为者（主要是非洲人）， ‐‐ 和西班牙裔美国人），以维持队列。加州大学洛杉矶分校CRS将提供领导和参与， 各工作组、综合传播战略范围内和地方的研究和研究出版物，以及多个合作伙伴， ‐ 队列研究，自35年前MACS成立以来一直如此。加州大学洛杉矶分校的CRS已经招募了大量的 团队的早期职业生涯和建立共同调查员从广泛的学科。这些研究者 已经制定并将继续制定创新建议，以促进我们对共同 在接受治疗的艾滋病毒感染者中出现的病态，以及病理生理学， 免疫学、遗传学和治疗和未治疗的HIV感染的生物行为特征。广度， 加州大学洛杉矶分校CRS调查人员的热情，经验和创新，结合经验和 长期工作人员的承诺，以及我们在艾滋病毒/艾滋病研究的几个领域的领导地位，将继续 在未来七年的CCS成功中发挥着宝贵的作用。

Abstract The UCLA Clinical Research Site (CRS) of the Multicenter AIDS Cohort Study (MACS) / Women's Interagency ‐ ‐ ‐‐ HIV Study (WIHS) Combined Cohort Study (CCS) proposes to continue to document clinical, immunologic, ‐‐ ‐ physiologic, behavioral, virologic, genetic and psychosocial changes in HIV infected and uninfected men who ‐‐ have sex with men (MSM). This includes proposed studies to document these changes in MSM recruited ‐ previously, as well as plans to recruit new untreated and recently treated HIV infected MSM (primarily African ‐‐ and Hispanic Americans), to maintain the cohort. The UCLA CRS will provide leadership and participation in the working groups, CCS wide and local studies and research publications, as well as collaborative multi ‐ cohort studies, as it has since the inception of the MACS 35 years ago. The UCLA CRS has recruited a large team of early career and established co investigators from a wide range of disciplines. These investigators have developed, and are continuing to develop, innovative proposals to advance our understanding of co- morbid conditions that arise in people living with treated HIV infection, as well as the pathophysiology, immunology, genetics a‐nd bio-behavioral characteristics of treated and untreated HIV infection. The breadth, enthusiasm, experience and innovation of the UCLA CRS investigators, combined with the experience and commitment of the long term staff, and our leadership of several areas of HIV/AIDs research, will continue to play an invaluable role in the success of the CCS over the next seven years.